Dr. Bergeson is currently an Associate Professor of Pharmacology and Neuroscience, Associate Dean of the Graduate School for Biomedical Sciences, and Director of the Biotechnology Master’s Program at TTUHSC. Her Alcohol Use Disorder research has been well-funded by NIH. She has also served on two permanent NIH study sections, AA2 and AA4, and numerous special review panels over many years. She currently is the Chair of the NURA study section for the Veterans Administration and is Co-Editor In Chief for the journal, Alcoholism Treatment Quarterly. In 2006, she was the organizing author of a PNAS paper, which brought together several alcohol researchers across the US with high throughput genomic datasets to complete a meta-analyses of their respective expression data. It, and subsequent follow-up studies, changed the field to a new focus on neuroimmune functioning as a translational target. She recently showed that inhibition of innate immune pathways reduced both binge and chronic drinking, as well as alcohol withdrawal symptoms. Dr. Bergeson has, together with her collaborators, filed patent protection for 72 compounds and is currently funded by two NIH grants to determine the best ‘lead’ and then complete pharmacology and toxicology studies for IND (investigational new drug) approval by the FDA. Her NIH awards were jointly funded to TTUHSC and South Plains Biotechnology, Inc., a TTUS HUB start-up company, in which she is a part owner.